Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Alhan, Canan
Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. [electronic resource] - Cytometry. Part B, Clinical cytometry May 2014 - 207-15 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1552-4957
10.1002/cyto.b.21160 doi
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic--therapeutic use
Azacitidine--therapeutic use
Biomarkers, Pharmacological--analysis
Bone Marrow Cells--classification
Female
Flow Cytometry
Humans
Immunophenotyping
Leukemia, Myeloid, Acute--drug therapy
Leukemia, Myelomonocytic, Chronic--drug therapy
Male
Middle Aged
Myelodysplastic Syndromes--drug therapy
Myeloid Progenitor Cells--classification
Prognosis
Research Design
Retrospective Studies
Risk Factors
Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. [electronic resource] - Cytometry. Part B, Clinical cytometry May 2014 - 207-15 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1552-4957
10.1002/cyto.b.21160 doi
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic--therapeutic use
Azacitidine--therapeutic use
Biomarkers, Pharmacological--analysis
Bone Marrow Cells--classification
Female
Flow Cytometry
Humans
Immunophenotyping
Leukemia, Myeloid, Acute--drug therapy
Leukemia, Myelomonocytic, Chronic--drug therapy
Male
Middle Aged
Myelodysplastic Syndromes--drug therapy
Myeloid Progenitor Cells--classification
Prognosis
Research Design
Retrospective Studies
Risk Factors